Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Hyperthyroxinemia”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

310 records · Page 18Linked to original sources

Thyroxine affects physiological and morphological development of the ear.

The onset and development of distortion product otoacoustic emissions (DPE) representing cochlear amplifier activity were studied in neonatal hyperthyroid (n = 10) and control (n = 10) rat pups. These were compared to the onset and development of auditory nerve-brainstem evoked responses (ABR) representing overall cochlear function, and to morphological development of the ear. DPEs were recorded at an earlier postnatal age to high (8 kHz) frequencies and progressed to lower (3 kHz) frequencies with age. ABRs to high-intensity clicks were recorded at least 2 days before DPEs, although DPE onset at 8 kHz preceded adult-like ABR thresholds. Both ABR and DPEs appeared earlier in the hyperthyroid rats. Histological evidence showed earlier morphological development of the ear in these animals. ABR thresholds and DPE amplitudes matured at a slower rate in the experimental group despite their earlier onset. There was no difference in ABR and DPE thresholds between adult hyperthyroid and control rats. However, in the experimental group, DPEs had smaller amplitudes to high (70 dB SPL) and to low (50 dB SPL) stimulus intensities at low frequencies. Hence, despite thyroxine-injected rat pups having earlier onset of auditory structure and function (lower ABR thresholds and earlier functioning active cochlear amplifier), it appeared that neonatal hyperthyroidism affected the later state of the cochlea, such that DPEs, especially to low-frequency stimuli, were depressed during and after maturation.

Acoustic Stimulation↗

Decreased reverse T3 levels in neonates with central hypothyroidism.

Concern arises when a sick infant is found to have a low serum T4, normal thyroid hormone binding, and a nonelevated thyroid-stimulating hormone. Hypothyroxinemia in this situation can result from either euthyroid sick syndrome or central hypothyroidism. To help distinguish between these diagnostic possibilities, we have measured reverse T3 and other thyroid function chemistries in six neonates who have central hypothyroidism in association with hypopituitarism. We found that these infants all had reverse T3 levels that were much lower than reported normal levels for premature and term neonates. This finding suggests that low reverse T3 levels can help to distinguish infants with central hypothyroidism from sick and well infants who tend to have relatively elevated reverse T3 levels.

Diagnosis, Differential↗

[The effect of antioxidants on lipid metabolism in myocardium in experimental hyperthyroxinemic conditions].

This experiment was conducted on 38 white Wistar-strain rats subdivided into five experimental groups. Group I were control animals which receiving intraperitoneal 0.5 ml injections of the sodium chloride physiological solution everyday during the whole experimental period of 26 days. Rats from Group II were injected intraperitoneally L-thyroxine (600 micrograms per kg of body weight) five times a week. The animals from Groups III, IV, and V, in addition to thyroxine injected in the same way as in Group II, were additionally administered one of such antioxidants as allopurinol, desferal, or vitamin C. The purpose of this research was to find an answer to the question whether the application of the above-mentioned antioxidants modifies the non-beneficial hyperthyroxinemic impact on the lipid metabolism of the cardiac muscle. It was found that the thyroxine influenced the change of the triglyceride and phospholipid contents in the cardiac muscle. All the applied antioxidants partly modified the thyroxine influence on the lipid balance in the cardiac muscle, especially in the area of triglycerides.

Allopurinol↗